Ignite Creation Date:
2024-05-19 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06413992
Status:
RECRUITING
Last Update Posted:
2024-05-14
First Post:
2024-04-23
Brief Title:
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Sponsor:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Organization:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Endometrial Carcinoma |
| TP53 Mutation |
| Recurrent or Metastatic |
Keywords:
| Name | View |
|---|---|
| TP53-mutated Endometrial CarcinomaCamrelizumab Fluzoparib | View |